Spero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 8, 2020 at 10:00 a.m. EDT to report its first quarter 2020 financial results and provide an update on its business and pipeline.

To access the call, please dial (855) 327-6837 (domestic) or (631) 891-4304 (international) and refer to conference ID 10009477. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at .  The archived webcast will also be available on Spero’s website for 30 days following the call. 

About Spero

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.

Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of rare, orphan disease caused by pulmonary non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit .

Spero Investor and Media Contact:

Sharon Klahre

Senior Director, Investor Relations

857-242-1547